88 completed, 10 terminated, 5 unknown, 5 withdrawn. 57 Phase 4, 28 Phase 3, 9 Phase 2, 5 Not applicable, 1 Phase 1.
Follow Travoprost: new trials by email Literature Review of Travoprost trials Research Report on Travoprost
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Observational Trial of the Updated Inserter for the Travoprost Intracameral Implant 75mcg Travoprost - Open Angle Glaucoma (OAG), Ocular Hypertension (OH) | Recruiting | Glaukos Corporation | 30 | 2025-12-17 | 2026-02-27 | |
| Preservative-free Fixed-dose Combination of Tafluprost 0.0015% / Timolol 0.5% in Patients With Open-angle Glaucoma or Ocular Hypertension: Clinical Effectiveness, Tolerability and Safety in a Real World Setting Tafluprost, timolol maleate - Ocular Surface Disease, Primary Open Angle Glaucoma | Completed | Santen Pharmaceutical (Taiwan) Co., LTD | 50 | 2021-09-01 | 2022-10-31 | |
| Effect Of Topical Prostaglandin F2α Analogs,Fractional CO2 Laser, Excimer Laser Or Their Combination In Treatment Of Vitiligo Topical travoprost 0.004% solution, Fractional CO2 laser, Excimer laser - Vitiligo, Excimer Laser | Phase 4 | Unknown | Assiut University | 30 | 2021-01-01 | 2020-10-22 |
| Study of Exchange of Travoprost Intraocular Implant Travoprost - Open Angle Glaucoma | Phase 2 | Completed | Glaukos Corporation | 33 | 2020-11-19 | 2023-09-26 |
| Interval Intraocular Pressure in Intravitreal Injection Study Timolol, Travatan, Hypromellose - Glaucoma, Intraocular Pressure | Not applicable | Completed | The University of Hong Kong | 64 | 2019-10-01 | 2021-04-30 |
| Comparison Between Latanoprost , Travoprost and Tafluprost in Reducing IOP Fluctuation in POAG Patients Latanoprost 0.005% Ophthalmic Solution, Travoprost 0.004% ophthalmic solution, Tafluprost Ophthalmic 0.0015% Ophthalmic Solution - Primary Open Angle Glaucoma | Completed | Kasr El Aini Hospital | 60 | 2019-06-01 | 2020-07-08 | |
| Safety and Tolerability of the Ophthalmic Solution PRO-179 Compared With Travatan® PRO 179, Travatan 0.004 % Ophthalmic Solution - Glaucoma | Phase 1 | Completed | Laboratorios Sophia S.A de C.V. | 24 | 2019-04-24 | 2019-12-12 |
| Additive Effect of Twice-daily Brinzolamide 1%/Brimonidine 0.2%Combination as an Adjunctive Therapy to Travoprost in Patients With Normal Tension Glaucoma brinzolamide 1%/brimonidine 0.2% fixed combination, Placebo, travoprost 0.004% ophthalmic solution - Glaucoma | Phase 4 | Completed | Novartis Pharmaceuticals | 1 | 2017-09-21 | 2019-02-25 |
| Phase 3 Study Evaluating Safety and Efficacy of OTX-TP in Subjects With OAG or OHT Travoprost, Placebo Vehicle - Open Angle Glaucoma, Ocular Hypertension | Phase 3 | Completed | Ocular Therapeutix, Inc. | 565 | 2016-11-07 | 2021-10-11 |
| Generic Travoprost Versus Brand Name Travoprost in Patients With Primary Open Angle Glaucoma or Ocular Hypertension Brand name travoprost, Generic travoprost - Glaucoma, Primary Open Angle, Ocular Hypertension | Phase 4 | Completed | Université de Sherbrooke | 76 | 2016-07-01 | 2020-12-01 |
| Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV® Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution - Open-angle Glaucoma, Ocular Hypertension | Phase 4 | Terminated | Alcon Research | 173 | 2016-06-24 | 2019-05-29 |
| Stop Retinal Ganglion Cell Dysfunction Study Latanoprost, Bimatoprost, Travoprost - Glaucoma | Phase 3 | Terminated | University of Miami | 28 | 2015-09-01 | 2025-08-26 |
| The Secondary Beneficial Effects of Prostaglandin Analog Treatment in Thyroid Eye Disease Patients. Prostaglandin Analog, Timolol - Thyroid Eye Disease, Ocular Hypertension | Phase 4 | Withdrawn | Stanford University | 2014-06-01 | 2018-05-15 | |
| 6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension Dose Level A / Brinzolamide 1% ophthalmic suspension, Dose Level B / Brinzolamide 1% ophthalmic suspension, Dose Level C / Brinzolamide 1% ophthalmic suspension - Glaucoma, Ocular Hypertension | Phase 2 | Completed | Alcon Research | 327 | 2014-06-01 | 2015-12-29 |
| Efficacy and Safety Study of Bimatoprost 0.01% Alone Compared With Travoprost 0.004% and Timolol 0.5% in Subjects With Glaucoma or Ocular Hypertension bimatoprost 0.01%, travoprost 0.004%, timolol 0.5% - Glaucoma, Ocular Hypertension | Phase 4 | Completed | Allergan | 100 | 2014-05-01 | 2016-01-14 |
| Effect of Selective Laser Trabeculoplasty Versus Travoprost on Circardian Intraocular Pressure Selective laser trabeculoplasty, Travoprost - Intraocular Pressure | Phase 4 | Completed | Prince of Songkla University | 60 | 2014-03-01 | 2016-08-08 |
| Choroidal Thickness and Its Correlations With Ocular Parameters in Primary Open-angle Glaucoma Brimonidine Tartrate, Dorzolamide (as Dorzolamide Hydrochloride) 20 Mg/mL and Timolol (as Timolol Maleate) 5 Mg/mL Eye Drops, Brinzolamide/Timolol 10 MG/1 ML-5 MG/1 ML Ophthalmic Suspension - Glaucoma, Open-Angle | Phase 4 | Completed | Afyon Kocatepe University Hospital | 96 | 2014-01-01 | 2019-05-29 |
| Efficacy of Travoprost/Timolol for Uncontrolled Intraocular Pressure Beta-blocker monotherapy, Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution - Open Angle Glaucoma, Ocular Hypertension | Phase 4 | Completed | Alcon Research | 157 | 2013-12-01 | 2016-08-08 |
| Effect of SIMBRINZA® Suspension as an Added Therapy to a Prostaglandin Analogue Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, Prostaglandin analogue - Ocular Hypertension, Open Angle Glaucoma | Phase 4 | Completed | Alcon Research | 282 | 2013-10-01 | 2015-07-28 |
| Effect of SIMBRINZA® Suspension as an Added Therapy to TRAVATAN Z® Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension, Vehicle, Travoprost 0.004% ophthalmic solution - Ocular Hypertension, Open Angle Glaucoma | Phase 4 | Completed | Alcon Research | 307 | 2013-10-01 | 2015-05-14 |
Showing 20 of 109. Sign in to see all of them.
Ocular Hypertension (75) · Glaucoma, Open-Angle (64) · Glaucoma (63) · Hypertension (8) · Patient Compliance (4) · Glaucoma, Angle-Closure (3) · Dry Eye Syndromes (2) · Exfoliation Syndrome (2) · Hyperemia (2) · Low Tension Glaucoma (2) · Cardiovascular Diseases (1) · Eye Diseases (1) · Glaucoma, Neovascular (1) · Graves Disease (1) · Graves Ophthalmopathy (1)
Alcon Research (62) · Allergan (6) · Glaukos Corporation (5) · Aristotle University Of Thessaloniki (3) · Aerie Pharmaceuticals (1) · Afyon Kocatepe University Hospital (1) · Assiut University (1) · Centre de recherche du Centre hospitalier universitaire de Sherbrooke (1) · Credit Valley EyeCare (1) · Federal University of São Paulo (1) · Hermann Eye Center (1) · Innovative Medical (1) · Kasr El Aini Hospital (1) · Laboratorios Sophia S.A de C.V. (1) · Massachusetts Eye and Ear Infirmary (1)
United States (32) · Canada (7) · Armenia (3) · Brazil (3) · Greece (3) · Italy (3) · Belgium (2) · Germany (2) · Japan (2) · Mexico (2) · Singapore (2) · Spain (2) · United Kingdom (2) · Australia (1) · China (1)
Abayomi Ogundele, PharmD (3) · Theresa Landry, PhD (3) · Anna Grau (2) · Lilit A Voskanyan, MD, PhD (2) · Pamela Smith, B.S. (2) · Steve Burmaster, PhD (2) · Theresa Landry (2) · Adriana S. Bonadia (1) · Alan L. Robin, MD (1) · Alana M Santana, MD (1) · Amandeep S Rai, MD (1) · Anastasios GP Konstas, MD, PhD (1)
PMID 17686450, PMID 18414108, PMID 19668762, PMID 20505839, PMID 21773673, PMID 23475405, PMID 24006861, PMID 25429421, PMID 25432143, PMID 26563363, PMID 27450828, PMID 2788589, PMID 28239491, PMID 28617732, PMID 34707360, PMID 41832303
2008 (2), 2016 (1), R01EY014957 (1)